Drugs / Healive
last change Oct 2023 re-read 2 minutes ago

Healive

Vaccine

Developed for
hepatitis A virus infection
Investigated by
Sinovac Biotech Co., Ltd · Liaoning Center for Disease Control and Prevention

Trials 3 · a red edge is where a trial was stopped

20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT06058416 Oct 2023 → Mar 2028 expected hepatitis A virus infection Sinovac Biotech Co., Ltd Active not recruiting No outcome recorded
Phase 4 NCT01252680 Apr 2010 → Feb 2011 hepatitis A virus infection Sinovac Biotech Co., Ltd Completed No outcome recorded
Phase 4 NCT00534885 Mar 2006 → Oct 2017 hepatitis A virus infection Sinovac Biotech Co., Ltd Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Healive ClinicalTrials.gov intervention name — accepted as the source's own label NCT06058416
2

NCT01252680

NCT00534885

Modality Vaccine “preservative-free inactivated hepatitis A vaccineNCT00534885